Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.

Nilsson P, Gunnlaugsson A, Beckman L, Widmark A, Fransson P, Hoyer M, Lagerlund M, Kindblom J, Johansson B, Björnlinger K, Ginman C, Olsson M, Agrup M, Kjellén E, Zackrisson B, Tavelin B, Franzén L, Anderson H, Thellenberg Karlsson C.

Open source

DOI: 10.1016/s1470-2045(25)00656-4
Published: 2026-02-05
Container: Lancet Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00656-4,
  title = {Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.},
  author = {Nilsson P and  Gunnlaugsson A and  Beckman L and  Widmark A and  Fransson P and  Hoyer M and  Lagerlund M and  Kindblom J and  Johansson B and  Björnlinger K and  Ginman C and  Olsson M and  Agrup M and  Kjellén E and  Zackrisson B and  Tavelin B and  Franzén L and  Anderson H and  Thellenberg Karlsson C.},
  year = {2026},
  journal = {Lancet Oncol},
  doi = {10.1016/s1470-2045(25)00656-4},
  url = {https://doi.org/10.1016/s1470-2045(25)00656-4}
}

RIS

TY  - JOUR
TI  - Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.
AU  - Nilsson P
AU  -  Gunnlaugsson A
AU  -  Beckman L
AU  -  Widmark A
AU  -  Fransson P
AU  -  Hoyer M
AU  -  Lagerlund M
AU  -  Kindblom J
AU  -  Johansson B
AU  -  Björnlinger K
AU  -  Ginman C
AU  -  Olsson M
AU  -  Agrup M
AU  -  Kjellén E
AU  -  Zackrisson B
AU  -  Tavelin B
AU  -  Franzén L
AU  -  Anderson H
AU  -  Thellenberg Karlsson C.
PY  - 2026
JO  - Lancet Oncol
DO  - 10.1016/s1470-2045(25)00656-4
UR  - https://doi.org/10.1016/s1470-2045(25)00656-4
ER  -

APA

P, N., A, G., L, B., A, W., P, F., M, H., M, L., J, K., B, J., K, B., C, G., M, O., M, A., E, K., B, Z., B, T., L, F., H, A., & C., T. K. (2026). Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.. Lancet Oncol. https://doi.org/10.1016/s1470-2045(25)00656-4

Source records

europe-pmc · retrieved 2026-09-27T04:08:29.388Z